---
figid: PMC4019832__210_2014_967_Fig2_HTML
figtitle: Activation, signalling and targeting of ErbB receptor family members
organisms:
- Homo sapiens
- Mus musculus
- clinical samples
- Moolgarda engeli
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC4019832
filename: 210_2014_967_Fig2_HTML.jpg
figlink: /pmc/articles/PMC4019832/figure/Fig2/
number: F2
caption: Schematic representation of activation, signalling and targeting of ErbB
  receptor family members. Overexpression or mutation of ErbB family members (EGFR,
  HER2, ErbB3 or ErbB4) or overexpression/translocation of ErbB growth factors results
  in the formation of ErbB homo- and heterodimers; for simplicity only, one heterodimer
  (EGFR:HER2) is shown here but all homo- and heterodimer combinations between the
  four monomers are possible. Dimerization leads to the formation of asymmetric head-to-tail
  complexes of the intracellular kinase domains resulting in transphosphorylation
  and receptor dimer activation resulting in downstream signalling. ErbB pathway engagement
  increases cell proliferation, angiogenesis, migration, metastasis and invasion,
  reduction of apoptosis and/or resistance to radiation and chemotherapy. Anti-ErbB
  monoclonal antibodies can be directed against EGFR (e.g. cetuximab and panitumab),
  HER2 (e.g. pertuzumab and trastuzumab) or ErbB3 (e.g. MM121). Small molecule TKIs
  can be EGFR-specific (e.g. erlotinib and gefitinib), dual EGFR/HER2 (e.g. lapatinib)
  or pan-ErbB blockers (e.g. afatinib and canertinib)
papertitle: A comprehensive review of the preclinical efficacy profile of the ErbB
  family blocker afatinib in cancer.
reftext: Helmout Modjtahedi, et al. Naunyn Schmiedebergs Arch Pharmacol. 2014;387(6):505-521.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9676019
figid_alias: PMC4019832__F2
figtype: Figure
redirect_from: /figures/PMC4019832__F2
ndex: 10b414a4-deb7-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4019832__210_2014_967_Fig2_HTML.html
  '@type': Dataset
  description: Schematic representation of activation, signalling and targeting of
    ErbB receptor family members. Overexpression or mutation of ErbB family members
    (EGFR, HER2, ErbB3 or ErbB4) or overexpression/translocation of ErbB growth factors
    results in the formation of ErbB homo- and heterodimers; for simplicity only,
    one heterodimer (EGFR:HER2) is shown here but all homo- and heterodimer combinations
    between the four monomers are possible. Dimerization leads to the formation of
    asymmetric head-to-tail complexes of the intracellular kinase domains resulting
    in transphosphorylation and receptor dimer activation resulting in downstream
    signalling. ErbB pathway engagement increases cell proliferation, angiogenesis,
    migration, metastasis and invasion, reduction of apoptosis and/or resistance to
    radiation and chemotherapy. Anti-ErbB monoclonal antibodies can be directed against
    EGFR (e.g. cetuximab and panitumab), HER2 (e.g. pertuzumab and trastuzumab) or
    ErbB3 (e.g. MM121). Small molecule TKIs can be EGFR-specific (e.g. erlotinib and
    gefitinib), dual EGFR/HER2 (e.g. lapatinib) or pan-ErbB blockers (e.g. afatinib
    and canertinib)
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - Erbb3
  - Erbb4
  - Erbb2
  - tk
  - Grb2
  - ras
  - Hras
  - Kras
  - Rem1
  - Shc1
  - Pik3r1
  - Pten
  - Zhx2
  - Akt1
  - Mdk
  - Mtor
  - Ephb2
  - Mapk1
  - Myc
  - Nol3
  - Jun
  - Fos
  - Nfkb1
  - EGFR
  - ERBB2
  - ERBB3
  - ERBB4
  - TK1
  - TK2
  - GRB2
  - KRAS
  - HRAS
  - NRAS
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - XYLT2
  - SOS1
  - SOS2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PTEN
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - MTOR
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - EPHB2
  - MAPK1
  - MAPK3
  - MYC
  - JUN
  - JUNB
  - JUND
  - FOS
  - FOSB
  - FOSL1
  - FOSL2
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Tk
  - drk
  - Ras64B
  - Ras85D
  - Shc
  - Sos
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Raf
  - Akt
  - hop
  - bsk
  - Dsor1
  - Mtk
  - Stat92E
  - Tor
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - Erk7
  - rl
  - CycE
  - cyc
  - Jra
  - kay
  - Dif
  - dl
  - Rel
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
